These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 35140619)

  • 1. Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.
    Chen H; Chen W; Yuan F; Guo Q; Zhang X; Wang C; Li X
    Front Pharmacol; 2022; 13():821944. PubMed ID: 35140619
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial.
    Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J
    Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects.
    Wang S; Yang X; Huang J; Yang S; Wu Q; Chen H; Wu S; Dou C; Yang G; Xiang Y
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1133-1142. PubMed ID: 36045484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects.
    Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q
    Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
    Ding Y; Liu Y; Dou C; Guo S
    J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The similarity of pharmacokinetics, pharmacodynamics, safety, and immunogenicity between recombinant fully human anti-RANKL monoclonal antibody injection (MW032) and denosumab (Xgeva®) in healthy Chinese subjects: A single-center, randomized, double-blind, single-dose, parallel-controlled clinical study.
    Hou J; Hu Z; Xu W; Di Y; Song C; Wu F; Liu J; Guo Y
    Int Immunopharmacol; 2022 Jun; 107():108666. PubMed ID: 35286913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of QL1206 to Denosumab Among Chinese Healthy Subjects.
    Zhang H; Wu M; Zhu X; Li C; Li X; Sun J; Liu C; Liu Q; Wei W; Niu J; Ding Y
    Front Pharmacol; 2020; 11():01329. PubMed ID: 33132906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study.
    Lin Y; Yang H; Yang X; Guo C; Yang S; Yang G; Wu Q; Pan C; Sun C; Li C; He L; Huang J; Pei Q
    Expert Opin Investig Drugs; 2022 Oct; 31(10):1125-1132. PubMed ID: 36112084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males.
    Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S
    Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males.
    Vogg B; Poetzl J; El Galta R; Fuhr R; Schwebig A; Sekhar S
    Expert Opin Biol Ther; 2024; 24(1-2):91-100. PubMed ID: 38269652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects.
    Wang W; Zhang S; Dou C; Hu B; Song H; Qi F; Zhao Y; Li X; Zhou M; Xie J; Deng K; Wu Q; Ye L; Cui C; Liu L; Huang J; Yang G
    BioDrugs; 2024 Nov; 38(6):855-865. PubMed ID: 39317850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.
    Reginster JY; Czerwinski E; Wilk K; Borowy P; Strzelecka A; Budlewski T; Janowska-Maus M; Szymanowski K; Kwiatek J; Postol S; Põder A; Supronik J; Kim S; Suh J; Han N; Kim N; Bae S; Silverman SL
    Osteoporos Int; 2024 Nov; 35(11):1919-1930. PubMed ID: 39042292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I Clinical Study Comparing the Tolerance, Immunogenicity, and Pharmacokinetics of Proposed Biosimilar BAT1806 and Reference Tocilizumab in Healthy Chinese Men.
    Zhang H; Wang H; Wei H; Chen H; Liu J; Li C; Zhu X; Li X; Yu J; Zhou Y; Yang X; Wang Z; Wu M; Ding Y
    Front Pharmacol; 2020; 11():609522. PubMed ID: 33569002
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized phase-I pharmacokinetic trial comparing the potential biosimilar tocilizumab (QX003S) with the reference product (Actemra
    Zhang H; Li X; Liu J; Li C; Wu M; Zhu X; Sun J; Fang M; Ding Y
    Ann Med; 2021 Dec; 53(1):375-383. PubMed ID: 33629921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA
    Cao G; Wang J; He J; Hu Y; Yang H; Que L; Gu X; Yu J; Wu X; Wu J; Fang W; He Q; Zhang J
    Front Pharmacol; 2023; 14():1111893. PubMed ID: 37081963
    [No Abstract]   [Full Text] [Related]  

  • 16. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects.
    Singh I; Attrey A; Garg A; Patel R; Jose V
    Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study.
    Chen Q; Hu C; Liu Y; Song R; Zhu W; Zhao H; Nino A; Zhang F; Liu Y
    PLoS One; 2018; 13(6):e0197984. PubMed ID: 29933364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Totality of Evidence for SDZ-deno: A Biosimilar to Reference Denosumab.
    Vogg B; Poetzl J; Schwebig A; Sekhar S; Kivitz A; Krivtsova N; Renner O; Body JJ; Eastell R
    Clin Ther; 2024 Nov; 46(11):916-926. PubMed ID: 39294041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects.
    Huang K; Que L; Ding Y; Chu N; Qian Z; Shi Y; Qin W; Li Z; Chen Y; Gu X; Wang J; Zhang L; Zhang J; Zhu X; Yang Y; Tang Y; He Q
    Front Pharmacol; 2021; 12():694375. PubMed ID: 34220519
    [No Abstract]   [Full Text] [Related]  

  • 20. GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar.
    von Richter O; O'Reilly T; Guerrieri D; Fan J; Fey C; Schussler S; Furlan F; Lemke L
    Expert Opin Biol Ther; 2023; 23(8):749-758. PubMed ID: 36039657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.